New financing will enable Atomwise to further scale the largest artificial intelligence (AI)-driven drug discovery portfolio in history and expand $5 billion+ deal pipeline for small molecule drug discovery SAN FRANCISCO — August 11, 2020 — Atomwise, the company deciphering human disease via the largest AI-drug discovery portfolio, announced today that it has closed $123 […]
[TechCrunch] With a slew of partnerships with large pharmaceutical companies under its belt and the successful spin out of at least one new company, Atomwise has already proved the value of its machine learning platform for discovering and commercializing potential small molecule therapies for a host of conditions.
[Wall Street Journal] Atomwise Inc., which uses artificial intelligence to help academic and commercial scientists discover new medicines, has raised $123 million to expand and build its own pipeline of experimental drugs.
The University of Kentucky (UK) has announced a research collaboration with Atomwise to explore potential COVID-19 therapies. An associate professor in UK’s college of medicine was granted the project from Atomwise’s Artificial Intelligence (AI) Molecular Screen award program, which seeks to democratize access to AI for drug discovery and enable researchers to accelerate the translation of their research into novel […]
On May 21, 2020, Atomwise announced 15 research collaborations to accelerate exploration of broad-spectrum therapies for COVID-19 and other coronaviruses with targets such as the Spike-ACE2, IL-6 Signaling Pathway, Nucleocapsid (N-protein), NSP15, Papain-Like Protease (PLpro), RdRp in NSP12, and Spike (heptad region).
Artificial intelligence (AI) is amplifying the pace of drug development, allowing developers to attack otherwise intractable problems and achieve results in weeks. Previously, results may have been impossible within any time frame.